Dimethylarginine Dimethylaminohydrolase1 Is an Organ-Specific Mediator of End Organ Damage in a Murine Model of Hypertension

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Sydow, Karsten ^a   Schmitz, Christine ^a   von Leitner, Eike Christin ^a   von Leitner, Robin ^b   Klinke, Anna ^a   Atzler, Dorothee ^b   Krebs, Christian ^b   Wieboldt, Hartwig ^a   Ehmke, Heimo ^b   Schwedhelm, Edzard ^b   Meinertz, Thomas ^a   Blankenberg, Stefan ^a   Böger, Rainer H ^b   Magnus, Tim ^b   Baldus, Stephan ^a   Wenzel, Ulrich ^b  

^a UNIVERSITY HEART CENTER HAMBURG   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DIMETHYLARGININASE; DIMETHYLARGININASE 1; N(G),N(G) DIMETHYLARGININE; UNCLASSIFIED DRUG;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME BLOOD LEVEL; ENZYME DEGRADATION; ENZYME METABOLISM; FEMALE; GENE OVEREXPRESSION; GENETIC ANALYSIS; HEART FAILURE; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HYPERTENSION; KIDNEY FUNCTION; MALE; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PATHOGENESIS; RENOVASCULAR HYPERTENSION; UREA NITROGEN BLOOD LEVEL; VASODILATATION;

AMIDOHYDROLASES; ANIMALS; ARGININE; BLOOD PRESSURE; HEART; HUMANS; HYPERTENSION; KIDNEY; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC;

MURINAE; MUS;

EID: 84868117569     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0048150     Document Type: Article

References (51)

1. Harrison DG, (1994) Endothelial dysfunction in atherosclerosis. Basic Res Cardiol 89Suppl 1: 87-102.
2. Zoccali C, Bode-Boger S, Mallamaci F, Benedetto F, Tripepi G, et al. (2001) Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet. 358: 2113-2117.
3. Schnabel R, Blankenberg S, Lubos E, Lackner KJ, Rupprecht HJ, et al. (2005) Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study. Circ Res 97: e53-59.
4. Boger RH, Sullivan LM, Schwedhelm E, Wang TJ, Maas R, et al. (2009) Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community. Circulation 119: 1592-1600.
5. Martens CR, Edwards DG (2011) Peripheral vascular dysfunction in chronic kidney disease. Cardiol Res Pract 267257.
6. Zhou X, Frohlich ED, (2007) Analogy of cardiac and renal complications in essential hypertension and aged SHR or L-NAME/SHR. Med Chem 3: 61-65.
7. Boger RH, Maas R, Schulze F, Schwedhelm E, (2009) Asymmetric dimethylarginine (ADMA) as a prospective marker of cardiovascular disease and mortality-an update on patient populations with a wide range of cardiovascular risk. Pharmacol Res. 60: 481-487.
8. Fujimi-Hayashida A, Ueda S, Yamagishi S, Kaida Y, Ando R, et al. (2011) Association of asymmetric dimethylarginine with severity of kidney injury and decline in kidney function in IgA nephropathy. Am J Nephrol 33: 1-6.
9. Fliser D, Kronenberg F, Kielstein JT, Morath C, Bode-Boger SM, et al. (2005) Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol 16: 2456-2461.
10. Ravani P, Tripepi G, Malberti F, Testa S, Mallamaci F, et al. (2005) Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. J Am Soc Nephrol 16: 2449-2455.
11. Baylis C, (2008) Nitric oxide deficiency in chronic kidney disease. Am J Physiol Renal Physiol 294: F1-9.
12. Ogawa T, Kimoto M, Sasaoka K, (1989) Purification and properties of a new enzyme, NG,NG-dimethylarginine dimethylaminohydrolase, from rat kidney. J Biol Chem 264: 10205-10209.
13. Leiper JM, Santa Maria J, Chubb A, MacAllister RJ, Charles IG, et al. (1999) Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases. Biochem J 343: 209-214.
14. Dayoub H, Achan V, Adimoolam S, Jacobi J, Stuehlinger MC, et al. (2003) Dimethylarginine dimethylaminohydrolase regulates nitric oxide synthesis: genetic and physiological evidence. Circulation 108: 3042-3047.
15. Konishi H, Sydow K, Cooke JP, (2007) Dimethylarginine dimethylaminohydrolase promotes endothelial repair after vascular injury. J Am Coll Cardiol 49: 1099-1105.
16. Stuhlinger MC, Conci E, Haubner BJ, Stocker EM, Schwaighofer J, et al. (2007) Asymmetric dimethyl L-arginine (ADMA) is a critical regulator of myocardial reperfusion injury. Cardiovasc Res 75: 417-425.
17. Sydow K, Mondon CE, Schrader J, Konishi H, Cooke JP, (2008) Dimethylarginine dimethylaminohydrolase overexpression enhances insulin sensitivity. Arterioscler Thromb Vasc Biol 28: 692-697.
18. Leypoldt F, Choe CU, Gelderblom M, von Leitner EC, Atzler D, et al. (2009) Dimethylarginine dimethylaminohydrolase-1 transgenic mice are not protected from ischemic stroke. PLoS ONE. 4: e7337.
19. von Leitner EC, Klinke A, Atzler D, Slocum JL, Lund N, et al. (2011) Pathogenic cycle between the endogenous nitric oxide synthase inhibitor asymmetrical dimethylarginine and the leukocyte-derived hemoprotein myeloperoxidase. Circulation 124: 2735-2745.
20. Kirchhoff F, Krebs C, Abdulhag UN, Meyer-Schwesinger C, Maas R, et al. (2008) Rapid development of severe end-organ damage in C57BL/6 mice by combining DOCA salt and angiotensin II. Kidney Int 73: 643-650.
21. Ishola DA Jr, van der Giezen DM, Hahnel B, Goldschmeding R, Kriz W, et al. (2006) In mice, proteinuria and renal inflammatory responses to albumin overload are strain-dependent. Nephrol Dial Transplant 21: 591-597.
22. Kren S, Hostetter TH, (1999) The course of the remnant kidney model in mice. Kidney Int 56: 333-337.
23. Wesseling S, Ishola DA Jr, Joles JA, Bluyssen HA, Koomans HA, et al. (2005) Resistance to oxidative stress by chronic infusion of angiotensin II in mouse kidney is not mediated by the AT2 receptor. Am J Physiol Renal Physiol 288: F1191-1200.
24. Krebs C, Fraune C, Schmidt-Haupt R, Turner JE, Panzer U, et al. (2012) CCR5 Deficiency Does Not Reduce Hypertensive End-Organ Damage in Mice. Am J Hypertens 25: 479-486.
25. Schwedhelm E, Maas R, Tan-Andresen J, Schulze F, Riederer U, et al. (2007) High-throughput liquid chromatographic-tandem mass spectrometric determination of arginine and dimethylated arginine derivatives in human and mouse plasma. J Chromatogr B 851: 211-219.
26. Munzel T, Giaid A, Kurz S, Stewart DJ, Harrison DG, (1995) Evidence for a role of endothelin 1 and protein kinase C in nitroglycerin tolerance. Proc Nat Acad Sci USA 92: 5244-5248.
27. Daiber A, Oelze M, Sulyok S, Coldewey M, Schulz E, et al. (2005) Heterozygous deficiency of manganese superoxide dismutase in mice (Mn-SOD+/-): a novel approach to assess the role of oxidative stress for the development of nitrate tolerance. Mol Pharmacol 68: 579-588.
28. Krebs C, Hamming I, Sadaghiani S, Steinmetz OM, Meyer-Schwesinger C, et al. (2007) Antihypertensive therapy upregulates renin and (pro)renin receptor in the clipped kidney of Goldblatt hypertensive rats. Kidney Int 72: 725-730.
29. Perticone F, Sciacqua A, Maio R, Perticone M, Maas R, et al. (2005) Asymmetric dimethylarginine, L-arginine, and endothelial dysfunction in essential hypertension. J Am Coll Cardiol 46: 518-523.
30. Surdacki A, Nowicki M, Sandmann J, Tsikas D, Boeger RH, et al. (1999) Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol 33: 652-658.
31. Meinitzer A, Seelhorst U, Wellnitz B, Halwachs-Baumann G, Boehm BO, et al. (2007) Asymmetrical dimethylarginine independently predicts total and cardiovascular mortality in individuals with angiographic coronary artery disease (the Ludwigshafen Risk and Cardiovascular Health study). Clin Chem 53: 273-283.
32. Palm F, Onozato ML, Luo Z, Wilcox CS, (2007) Dimethylarginine dimethylaminohydrolase (DDAH): expression, regulation, and function in the cardiovascular and renal systems. Am J Physiol Heart Circ Physiol 293: H3227-3245.
33. Kielstein JT, Veldink H, Martens-Lobenhoffer J, Haller H, Perthel R, et al. (2011) Unilateral nephrectomy causes an abrupt increase in inflammatory mediators and a simultaneous decrease in plasma ADMA: a study in living kidney donors. Am J Physiol Renal Physiol 301: F1042-1046.
34. Schwedhelm E, von Leitner EC, Atzler D, Schmitz C, Jacobi J, et al. (2009) Extensive characterization of the human DDAH1 transgenic mice. Pharmacol Res 60: 494-502.
35. Hu X, Atzler D, Xu X, Zhang P, Guo H, et al. (2011) Dimethylarginine dimethylaminohydrolase-1 is the critical enzyme for degrading the cardiovascular risk factor asymmetrical dimethylarginine. Arterioscler Thromb Vasc Biol 31: 1540-1546.
36. Kielstein JT, Impraim B, Simmel S, Bode-Boger SM, Tsikas D, et al. (2004) Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation 109: 172-177.
37. Achan V, Broadhead M, Malaki M, Whitley G, Leiper J, et al. (2003) Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol 23: 1455-1459.
38. Hu X, Xu X, Zhu G, Atzler D, Kimoto M, et al. (2009) Vascular endothelial-specific dimethylarginine dimethylaminohydrolase-1-deficient mice reveal that vascular endothelium plays an important role in removing asymmetric dimethylarginine. Circulation 120: 2222-2229.
39. Jacobi J, Maas R, Cordasic N, Koch K, Schmieder RE, et al. (2008) Role of asymmetric dimethylarginine for angiotensin II-induced target organ damage in mice. Am J Physiol Heart Circ Physiol 294: H1058-1066.
40. Sasser JM, Moningka NC, Cunningham MW Jr, Croker B, Baylis C, (2010) Asymmetric dimethylarginine in angiotensin II-induced hypertension. Am J Physiol Regul Integr Comp Physiol 298: R740-746.
41. Closs EI, Basha FZ, Habermeier A, Forstermann U, (1997) Interference of L-arginine analogues with L-arginine transport mediated by the y+ carrier hCAT-2B. Nitric Oxide 1: 65-73.
42. Tojo A, Welch WJ, Bremer V, Kimoto M, Kimura K, et al. (1997) Colocalization of demethylating enzymes and NOS and functional effects of methylarginines in rat kidney. Kidney Int 52: 1593-1601.
43. Deschepper CF, Boutin-Ganache I, Zahabi A, Jiang Z, (2002) In search of cardiovascular candidate genes: interactions between phenotypes and genotypes. Hypertension 39: 332-336.
44. Zhou MS, Adam AG, Jaimes EA, Raij L, (2003) In salt-sensitive hypertension, increased superoxide production is linked to functional upregulation of angiotensin II. Hypertension 42: 945-951.
45. Raij L, (1998) Nitric oxide in hypertension: relationship with renal injury and left ventricular hypertrophy. Hypertension 31: 189-193.
46. Ishibashi M, Hiasa K, Zhao Q, Inoue S, Ohtani K, et al. (2004) Critical role of monocyte chemoattractant protein-1 receptor CCR2 on monocytes in hypertension-induced vascular inflammation and remodeling. Circ Res 94: 1203-1210.
47. Liao TD, Yang XP, Liu YH, Shesely EG, Cavasin MA, et al. (2008) Role of inflammation in the development of renal damage and dysfunction in angiotensin II-induced hypertension. Hypertension 52: 256-263.
48. Tanaka M, Sydow K, Gunawan F, Jacobi J, Tsao PS, et al. (2005) Dimethylarginine dimethylaminohydrolase overexpression suppresses graft coronary artery disease. Circulation 112: 1549-1556.
49. Matsumoto Y, Ueda S, Yamagishi S, Matsuguma K, Shibata R, et al. (2007) Dimethylarginine dimethylaminohydrolase prevents progression of renal dysfunction by inhibiting loss of peritubular capillaries and tubulointerstitial fibrosis in a rat model of chronic kidney disease. J Am Soc Nephrol 18: 1525-1533.
50. Brilla CG, (2000) Aldosterone and myocardial fibrosis in heart failure. Herz 25: 299-306.
51. Kielstein JT, Veldink H, Martens-Lobenhoffer J, Haller H, Burg M, et al. (2011) SDMA is an early marker of change in GFR after living-related kidney donation. Nephrol Dial Transplant 26: 324-328.